Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine Arepanrix (GSK2340274A) in Adults 65 Years of Age or Older.
Phase of Trial: Phase IV
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 09 Jan 2013 Actual end date changed from Nov 2010 to Dec 2010 as reported by ClinicalTrials.gov.
- 02 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.